Global LATAM Adalimumab Market Size By Type (Oral Type, Injection Type), By Application (Rheumatoid Arthritis, Psoriasis), By Region, And Segment Forecasts, 2023 to 2032

The Global LATAM Adalimumab Market was valued at USD 1.1 billion in 2023 and is expected to reach USD 2.0 billion by 2031, growing at a CAGR of 7.7% during the forecast period (2023–2031). The market’s expansion is driven by the rising prevalence of autoimmune diseases in Latin America, increased access to biologic therapies, and the growing acceptance of biosimilar alternatives to adalimumab. Governments and private health insurers in LATAM are progressively integrating biologic treatments like adalimumab into reimbursement plans, supporting long-term therapy for conditions such as rheumatoid arthritis, Crohn’s disease, and plaque psoriasis.

Drivers:

1. Rising Burden of Autoimmune Disorders

Chronic inflammatory and autoimmune diseases are on the rise in LATAM, particularly rheumatoid arthritis, ankylosing spondylitis, and ulcerative colitis. Adalimumab, as a TNF inhibitor, plays a vital role in reducing inflammation and improving quality of life for patients, contributing to consistent market demand.

2. Increasing Adoption of Biosimilars

The expiration of Humira’s patent has opened the LATAM market to a wave of biosimilar entries. These lower-cost options are boosting accessibility and broadening patient treatment coverage, especially in cost-sensitive healthcare systems.

3. Expansion of Biologic Therapy Reimbursement Programs

LATAM countries such as Brazil, Mexico, and Argentina are expanding public healthcare policies to include biologic treatments. This has catalyzed the availability of adalimumab across public and private sectors.

Restraints:

1. High Cost of Original Biologics

Despite biosimilar competition, the original adalimumab formulations remain expensive. Budget constraints in public health systems and limited insurance coverage in rural regions hamper widespread access.

2. Regulatory Barriers and Complex Approval Pathways

Lengthy regulatory approvals and inconsistent biosimilar guidelines across LATAM nations delay product launches, particularly for smaller biopharma entrants, limiting market dynamism.

Opportunity:

1. Expansion of Biosimilar Portfolios by Regional Players

Local and regional pharmaceutical companies are increasingly developing or partnering to distribute adalimumab biosimilars. This creates growth avenues through cost-competitive offerings tailored to regional healthcare ecosystems.

2. Rising Investments in Healthcare Infrastructure

LATAM governments are prioritizing investments in healthcare access and chronic disease management. Improved diagnostics and specialist availability will lead to earlier biologic intervention, increasing demand for adalimumab.

Market by System Type Insights:

By formulation type, Pre-filled Syringes held the largest market share in 2023. They offer convenience, are ideal for self-administration, and are preferred in home-based treatment settings. Meanwhile, the Auto-injectors segment is expected to exhibit the fastest growth due to enhanced patient adherence and rising awareness about user-friendly biologic delivery devices.

Market by End-use Insights:

In terms of end use, Hospitals dominated the LATAM adalimumab market in 2023, owing to established treatment pathways and greater access to biologics through institutional supply chains. The Retail Pharmacies segment is growing significantly, driven by increasing patient preference for outpatient and home-based therapies.

Market by Regional Insights:

Brazil emerged as the leading country in the LATAM adalimumab market in 2023 due to its large population, robust public healthcare coverage, and rapid biosimilar integration. Mexico and Argentina follow, with rising pharmaceutical investments and favorable reimbursement frameworks. Chile and Colombia are also key growth markets, benefiting from progressive biologics policies.

Competitive Scenario:

Major players in the LATAM adalimumab market include AbbVie Inc., Amgen Inc., Pfizer Inc., Samsung Bioepis, Biogen Inc., Sandoz International GmbH, and Fresenius Kabi. These companies are focusing on pricing strategies, regional partnerships, and supply chain expansions. For instance:

In 2024, Sandoz launched a new biosimilar version of adalimumab across major LATAM countries, gaining significant market traction through its affordability and effectiveness.

AbbVie continues to invest in patient support programs to maintain brand loyalty for Humira despite biosimilar competition.

Amgen and Biogen have both expanded regional collaborations to distribute biosimilar offerings under flexible pricing models.

Scope of Work – Global LATAM Adalimumab Market

Key Market Developments:

2023: Pfizer launched Abrilada, a biosimilar to Humira, in Mexico and Brazil, supported by localized marketing campaigns and physician training programs.

2024: Fresenius Kabi received regulatory approval for its adalimumab biosimilar in Argentina and began distribution through public hospitals.

2025: Brazil’s ANVISA streamlined its biosimilar approval pathway, enabling faster market access for upcoming adalimumab biosimilars.

FAQs:

1) What is the current market size of the Global LATAM Adalimumab Market?

The market was valued at USD 1.1 billion in 2023.

2) What is the major growth driver of the Global LATAM Adalimumab Market?

The increasing prevalence of autoimmune diseases and adoption of cost-effective biosimilars are the primary growth drivers.

3) Which is the largest region during the forecast period in the Global LATAM Adalimumab Market?

Brazil is expected to maintain its lead, driven by strong public healthcare policies and rapid biosimilar uptake.

4) Which segment accounted for the largest market share in Global LATAM Adalimumab Market?

The Pre-filled Syringes segment led the market in 2023 due to ease of use and patient preference.

5) Who are the key market players in the Global LATAM Adalimumab Market?

Key players include AbbVie, Pfizer, Amgen, Samsung Bioepis, Biogen, Sandoz, and Fresenius Kabi.